HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit an electronic Letter to the Editor about this paper Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (12) Citing Articles via Google Scholar Google Scholar Articles by Massart, C. Articles by Maugendre, D. Search for Related Content PubMed PubMed Citation Articles by Massart, C. Articles by Maugendre, D. Related Collections Endocrinology and Metabolism

Importance of the Detection Method for Thyroglobulin Antibodies for the Validity of Thyroglobulin Measurements in Sera from Patients with Graves Disease

¹ Laboratoire de Génétique Moléculaire et Hormonologie et
² Unité d’Endocrinologie, CHU de Pontchaillou, Rue H. Le Guilloux, 35043 Rennes Cedex, France.

^aAuthor for correspondence. Fax 02-99-28-41-45; e-mail catherine.massart{at}chu-rennes.fr.

Background: The use of recovery tests has been proposed to disclose interferences from anti-thyroglobulin antibodies (TgAbs) in thyroglobulin (Tg) assays. We studied the value of a recovery test in Tg measurement by a new commercial IRMA.

Methods: Blood samples were collected from 153 patients with untreated Graves disease. Tg and TgAbs were measured by IRMA and RIA, respectively (Dynotest Tg-plus and Dynotest anti-Tgn; Brahms Diagnostica). The recoveries of added amounts of Tg were calculated for each serum.

Results: TgAbs were detected in 72 of the 153 patients (47%). The recovery test results for the 81 TgAb-negative sera (median, 101%; range, 80–115%) were identical to the results for the 91 controls (median, 102%; range, 80–124%). By contrast, significantly lower recovery test results were observed for the 72 TgAb-positive sera (median, 79%; range, 60–103%; Z = -8.363; P <0.0001). In the 34 of the 72 TgAb-positive sera with a normal recovery test, Tg concentrations were significantly lower (median Tg, 13.6 µg/L; range, 1.1–360 µg/L) than those measured in the TgAb-negative sera (median, 107 µg/L; range, 1.2–700 µg/L; Z = -3.797; P <0.0001).

Conclusions: Tg values were decreased in TgAb-positive sera even when the results of the recovery tests were normal. This test should not be used alone to determine the validity of a serum Tg measurement in Graves disease.

The following articles in journals at HighWire Press have cited this article:

				C. A. Spencer, L. M. Bergoglio, M. Kazarosyan, S. Fatemi, and J. S. LoPresti Clinical Impact of Thyroglobulin (Tg) and Tg Autoantibody Method Differences on the Management of Patients with Differentiated Thyroid Carcinomas J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5566 - 5575. [Abstract] [Full Text] [PDF]

				C. A. Spencer Challenges of Serum Thyroglobulin (Tg) Measurement in the Presence of Tg Autoantibodies J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3702 - 3704. [Full Text] [PDF]

				J. S. Krouwer Proposal to Add an Optional Recommendations Section to Clinical Chemistry Abstracts Clin. Chem., December 1, 2002; 48(12): 2292 - 2292. [Full Text] [PDF]